A combination treatment with thymosin α1 (200 μg/kg) for 4 days, followed by a single injection of murine interferon α/β (3 x 104 international units/mouse), starting 2 days after cyclophosphamide treatment (200 mg/kg, single injection) demonstrated a dramatic and rapid disappearance of tumor burden in mice bearing Lewis lung carcinoma (3LL) tumor. The effectiveness of this new chemoimmunotherapy protocol was evident even on the long-term survival in a high percentage of animals, and was statistically significant when compared to treatment with the single agents in conjunction with chemotherapy or to chemotherapy itself. The same combination immunotherapy treatment strongly stimulated natural killer activity and cytotoxicity against autologous 3LL tumor cells in 3LL-tumor-bearing mice treated with cyclophosphamide, whereas treatments with each agent singly did not alter or only slightly modified the cytotoxic activity towards Yac-1 or 3LL target cells. Selective depletion with antibodies showed that killer cells stimulated by combination chemoimmunotherapy treatment bear phenotypic characteristics of asialo-GM1-positive cells. A histological study has shown a high number of infiltrating lymphoid cells in the tumors obtained from mice treated with combination chemoimmunotherapy.

Garaci, E., Mastino, A., Pica, F., Favalli, C. (1990). combination treatment using thymosin alpha-1 and interferon after cyclophosphamide is able to cure lewis lung-carcinoma in mice. CANCER IMMUNOLOGY, IMMUNOTHERAPY, 32(3), 154-160 [10.1007/BF01771450].

combination treatment using thymosin alpha-1 and interferon after cyclophosphamide is able to cure lewis lung-carcinoma in mice

GARACI, ENRICO;PICA, FRANCESCA;FAVALLI, CARTESIO
1990-01-01

Abstract

A combination treatment with thymosin α1 (200 μg/kg) for 4 days, followed by a single injection of murine interferon α/β (3 x 104 international units/mouse), starting 2 days after cyclophosphamide treatment (200 mg/kg, single injection) demonstrated a dramatic and rapid disappearance of tumor burden in mice bearing Lewis lung carcinoma (3LL) tumor. The effectiveness of this new chemoimmunotherapy protocol was evident even on the long-term survival in a high percentage of animals, and was statistically significant when compared to treatment with the single agents in conjunction with chemotherapy or to chemotherapy itself. The same combination immunotherapy treatment strongly stimulated natural killer activity and cytotoxicity against autologous 3LL tumor cells in 3LL-tumor-bearing mice treated with cyclophosphamide, whereas treatments with each agent singly did not alter or only slightly modified the cytotoxic activity towards Yac-1 or 3LL target cells. Selective depletion with antibodies showed that killer cells stimulated by combination chemoimmunotherapy treatment bear phenotypic characteristics of asialo-GM1-positive cells. A histological study has shown a high number of infiltrating lymphoid cells in the tumors obtained from mice treated with combination chemoimmunotherapy.
1990
Pubblicato
Rilevanza internazionale
Articolo
Sì, ma tipo non specificato
Settore MED/07 - MICROBIOLOGIA E MICROBIOLOGIA CLINICA
English
Con Impact Factor ISI
alpha interferon; cyclophosphamide; thymosin; animal cell; animal model; animal tissue; article; controlled study; immunotherapy; intraperitoneal drug administration; lung carcinoma; mouse; natural killer cell; nonhuman; priority journal; Animal; Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Cyclophosphamide; Cytotoxicity, Immunologic; Immunotherapy; Interferon Type I; Interferon Type II; Killer Cells, Natural; Lung Neoplasms; Male; Mice; Mice, Inbred Strains; Phenotype; Support, Non-U.S. Gov't; Thymosin
Garaci, E., Mastino, A., Pica, F., Favalli, C. (1990). combination treatment using thymosin alpha-1 and interferon after cyclophosphamide is able to cure lewis lung-carcinoma in mice. CANCER IMMUNOLOGY, IMMUNOTHERAPY, 32(3), 154-160 [10.1007/BF01771450].
Garaci, E; Mastino, A; Pica, F; Favalli, C
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/50872
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 53
  • ???jsp.display-item.citation.isi??? 53
social impact